US-compounded peptides · COA on every batch · Free UAE delivery on all orders.
DXB Peptides

What Is Tesa? GHRH Analog Research Overview

Last updated: 9 June 2026

Supplied strictly for in vitro laboratory research. Not for human consumption.

Tesa is a synthetic analog of growth-hormone-releasing hormone (GHRH), and it occupies an unusual position among research peptides: it is the only GHRH analog to have achieved full regulatory approval as a medicine. Rather than supplying growth hormone directly, it stimulates the body’s own pituitary to release it. This guide summarises what tesa is, how it works, and what the research record shows, for research context only.

What is Tesa?

Tesa is a synthetic analog of human growth-hormone-releasing hormone — the full GHRH sequence with a trans-3-hexenoic acid group attached, a modification that makes the molecule more stable and extends its biological activity compared with native GHRH. Functionally, it is a growth hormone secretagogue: a compound that prompts the body to secrete its own growth hormone, as opposed to introducing growth hormone from outside.

Mechanism

  • GHRH receptor agonism — binds the GHRH receptor on somatotroph cells in the anterior pituitary, with higher affinity and longer activity than native GHRH.
  • Pulsatile GH release — stimulates the synthesis and pulsatile release of endogenous growth hormone, preserving the body’s natural rhythm and somatostatin feedback rather than overriding it.
  • IGF-1 elevation — the downstream rise in growth hormone increases IGF-1, the principal mediator of many of GH’s metabolic effects.
  • Short half-life — with a half-life of roughly 26–38 minutes, it triggers a discrete GH pulse and then clears, in contrast to longer-acting analogs that produce a sustained GH elevation.

An approved-medicine pedigree

Tesa is the active ingredient in Egrifta, approved by the US FDA in November 2010 for one specific indication: the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It remains the only GHRH analog with full FDA approval. That approval rested on pivotal Phase III trials (LIPO-010 and LIPO-011, involving more than 800 patients), which reported reductions in visceral adipose tissue on the order of 15–18% over 26 weeks, with the effect being selective for visceral rather than subcutaneous fat.

It is important to be precise here: this approval is narrow and specific to HIV-associated lipodystrophy. Any other application — general body composition, metabolic, or cognitive contexts — falls outside that approval and is investigational. Tesa has also been studied in research settings for liver fat (NAFLD/MASLD) and for cognition, but these are research areas, not approved uses.

Part of the GH-axis family

Tesa sits within the broader family of growth-hormone-axis peptides. It is frequently compared with CJC-1295 and Ipamorelin — other secretagogues that engage the same axis through related but distinct mechanisms. A key point of contrast is duration: tesa’s short half-life preserves a discrete, pulse-like GH release, whereas longer-acting analogs sustain elevation differently.

Research and sourcing considerations

As with any research peptide, reproducible results depend on verified identity and purity. Research-grade tesa should be supplied with independent HPLC purity testing (≥99% purity) and a batch-specific certificate of analysis (COA) for the specific vial supplied.

DXB Peptides supplies research-grade tesa for in vitro laboratory use — HPLC-tested to ≥99% purity with a batch-specific COA, cold-chain handled and delivered across the UAE.

Frequently asked questions

What is tesa? A synthetic GHRH analog that stimulates the pituitary to release the body’s own growth hormone, studied for its effects on the GH–IGF-1 axis.

How is it different from growth hormone? Tesa is a secretagogue — it prompts the body to produce GH, preserving natural pulsatile release and feedback, rather than supplying GH directly.

Is tesa FDA-approved? Yes — but only for one specific indication (reduction of excess abdominal fat in HIV-associated lipodystrophy). It is the only GHRH analog with full FDA approval; all other applications are investigational.

What purity should research-grade tesa be? Look for independent HPLC testing at ≥99% purity, accompanied by a batch-specific certificate of analysis.

Important note

The tesa supplied by DXB Peptides is a research compound for in vitro laboratory use only. It is not the approved medicine, is not supplied for any therapeutic purpose, and is not for human consumption or in vivo administration.

Explore the full catalogue: Research peptides UAE

Questions? Message me.